Premium
Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy
Author(s) -
Seferović Petar M.,
Tsutsui Hiroyuki,
McNamara Dennis M.,
Ristić Arsen D.,
Basso Cristina,
Bozkurt Biykem,
Cooper Leslie T.,
Filippatos Gerasimos,
Ide Tomomi,
Inomata Takayuki,
Klingel Karin,
Linhart Aleš,
Lyon Alexander R.,
Mehra Mandeep R.,
Polovina Marija,
Milinković Ivan,
Nakamura Kazufumi,
Anker Stefan D.,
Veljić Ivana,
Ohtani Tomohito,
Okumura Takahiro,
Thum Thomas,
Tschöpe Carsten,
Rosano Giuseppe,
Coats Andrew J.S.,
Starling Randall C.
Publication year - 2021
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1002/ejhf.2190
Subject(s) - medicine , heart failure , myocarditis , cardiology , position paper , intensive care medicine , cardiac amyloidosis , endomyocardial biopsy , pathology
Endomyocardial biopsy (EMB) is an invasive procedure, globally most often used for the monitoring of heart transplant (HTx) rejection. In addition, EMB can have an important complementary role to the clinical assessment in establishing the diagnosis of diverse cardiac disorders, including myocarditis, cardiomyopathies, drug‐related cardiotoxicity, amyloidosis, other infiltrative and storage disorders, and cardiac tumours. Improvements in EMB equipment and the development of new techniques for the analysis of EMB samples have significantly improved diagnostic precision of EMB. The present document is the result of the Trilateral Cooperation Project between the Heart Failure Association of the European Society of Cardiology, the Heart Failure Society of America, and the Japanese Heart Failure Society. It represents an expert consensus aiming to provide a comprehensive, up‐to‐date perspective on EMB, with a focus on the following main issues: (i) an overview of the practical approach to EMB, (ii) an update on indications for EMB, (iii) a revised plan for HTx rejection surveillance, (iv) the impact of multimodality imaging on EMB, and (v) the current clinical practice in the worldwide use of EMB.